Eledon Pharmaceuticals (NASDAQ:ELDN) Share Price Crosses Above 50-Day Moving Average – What’s Next?

Posted by George Bondi on Oct 29th, 2026

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Free Report) shares passed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $2.71 and traded as high as $2.81. Eledon Pharmaceuticals shares last traded at $2.76, with a volume of 2,075,852 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ELDN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Monday, September 21st. Rodman & Renshaw assumed coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, July 21st. They set a “buy” rating and a $12.00 target price on the stock. Finally, Wall Street Zen cut shares of Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 23rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Eledon Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $10.00.

View Our Latest Research Report on ELDN

Eledon Pharmaceuticals Trading Up 14.5%

The company has a market capitalization of $224.28 million, a price-to-earnings ratio of -3.03 and a beta of 0.84. The company has a 50 day moving average price of $2.71 and a 200 day moving average price of $3.08.

Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.11). Equities analysts predict that Eledon Pharmaceuticals, Inc. will post -0.74 earnings per share for the current year.

Institutional Trading of Eledon Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new stake in shares of Eledon Pharmaceuticals during the second quarter worth $20,188,000. Defilade Capital Management L.P. increased its holdings in Eledon Pharmaceuticals by 8.3% in the first quarter. Defilade Capital Management L.P. now owns 3,564,127 shares of the company’s stock valued at $10,978,000 after purchasing an additional 273,677 shares during the last quarter. AWM Investment Company Inc. bought a new stake in Eledon Pharmaceuticals in the second quarter valued at about $4,334,000. Bank of America Corp DE acquired a new position in Eledon Pharmaceuticals in the second quarter valued at about $3,479,000. Finally, ADAR1 Capital Management LLC acquired a new position in Eledon Pharmaceuticals in the second quarter valued at about $2,552,000. Institutional investors own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

(Get Free Report)

Eledon Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing therapies that selectively modulate the immune system for patients with life-threatening diseases. The company’s research is centered on conditions involving immune activation, including organ transplantation, autoimmune disorders and other inflammatory diseases.

Eledon’s lead product candidate is tegoprubart, a monoclonal antibody designed to block CD40 ligand, a protein involved in immune-system signaling.